Disease · MONDO_0006816

arthropathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. arthropathy. Diseases, record MONDO_0006816. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006816

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: arthropathy; Open Targets
Open Targets ID: MONDO_0006816; Open Targets
Other names: Disease of the joints, Joint disorder, disease of skeletal joint, disease or disorder of skeletal joint, disorder of skeletal joint, disorder, Joint, joint disease, skeletal joint disease, skeletal joint disease or disorder; Open Targets
Disease Ontology: DOID:381; Disease Ontology
MeSH: D007592; MeSH
NCI Thesaurus: C35760; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 7 drugs, from TTD; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IOTHALAMIC ACID	CHEMBL1201300	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ROFECOXIB	CHEMBL122	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SPRIFERMIN	CHEMBL2108302	Protein	Phase 2	TTD	1	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
EMICIZUMAB	CHEMBL3833393	Antibody	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
HYALURONIC ACID	CHEMBL5314376		Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVOBUPIVACAINE HYDROCHLORIDE	CHEMBL1200749	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
F10	Coagulation factor IX and X	1	Coagulation factor IX and X other	Unknown	https://conductscience.org/library/genes/2159	Drugs and targets
F9	Coagulation factor IX and X	1	Coagulation factor IX and X other	Unknown	https://conductscience.org/library/genes/2158	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Unknown	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS2	Prostaglandin G/H synthase 2	1	Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
SCN4A	Sodium channel protein type 4 subunit alpha	1	Sodium channel protein type IV alpha subunit blocker	Unknown	https://conductscience.org/library/genes/6329	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02601170	Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy	Not applicable	22	2020-09-17	Hemophilia, Hemophilic Arthropathy	HYALURONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03258697	The Pharmacokinetics and Effectiveness of Local LevoBupivacaine Injection on Primary Total Joint Replacement Model.	Not applicable	90		Arthropathy	LEVOBUPIVACAINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT05983055	Steroid Injection for Sickle Cell Arthropathy Pain Therapy		50		Sickle Cell Disease, Sickle Cell Abnormality	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT06104826	Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab		50		Hemophilia A	EMICIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04684511	Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy	Phase 3	2		Hemophilic Arthropathy	ROFECOXIB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
PRP Group vs HA Group: serious adverse events	0 of 11	0 of 11	22	NCT02601170

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006816

GET https://conductscience.org/api/diseases/v1/MONDO_0006816/drugs

API reference For AI assistants